Business Description
Interpace Biosciences Inc
NAICS : 541380
SIC : 8099
ISIN : US46062X2045
Description
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.31 | |||||
Equity-to-Asset | -4.74 | |||||
Debt-to-Equity | -0.18 | |||||
Debt-to-EBITDA | 2.97 | |||||
Interest Coverage | 3.75 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | -24.3 | |||||
Beneish M-Score | -3.11 | |||||
WACC vs ROIC |
Growth Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 4.6 | |||||
3-Year Book Growth Rate | -25.5 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 46.57 | |||||
9-Day RSI | 47.32 | |||||
14-Day RSI | 48.77 | |||||
6-1 Month Momentum % | 75.32 | |||||
12-1 Month Momentum % | 41.36 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.59 | |||||
Quick Ratio | 0.52 | |||||
Cash Ratio | 0.2 | |||||
Days Inventory | 35.31 | |||||
Days Sales Outstanding | 58.82 | |||||
Days Payable | 43.23 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.4 | |||||
Shareholder Yield % | 18.99 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 60.86 | |||||
Operating Margin % | 9.08 | |||||
Net Margin % | 4.55 | |||||
FCF Margin % | 7.6 | |||||
ROE % | Neg. Equity | |||||
ROA % | 9.43 | |||||
ROIC % | 41.93 | |||||
ROC (Joel Greenblatt) % | 87.09 | |||||
ROCE % | 336.79 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 4.25 | |||||
PE Ratio without NRI | 3.66 | |||||
Price-to-Owner-Earnings | 3.13 | |||||
PS Ratio | 0.19 | |||||
Price-to-Free-Cash-Flow | 2.5 | |||||
Price-to-Operating-Cash-Flow | 2.2 | |||||
EV-to-EBIT | 5.67 | |||||
EV-to-EBITDA | 3.62 | |||||
EV-to-Revenue | 0.44 | |||||
EV-to-Forward-Revenue | 0.44 | |||||
EV-to-FCF | 5.77 | |||||
Earnings Yield (Greenblatt) % | 17.64 | |||||
FCF Yield % | 39.75 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Interpace Biosciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 28.784 | ||
EPS (TTM) (€) | 0.295 | ||
Beta | 1 | ||
Volatility % | 187.75 | ||
14-Day RSI | 48.77 | ||
14-Day ATR (€) | 0.069986 | ||
20-Day SMA (€) | 1.267 | ||
12-1 Month Momentum % | 41.36 | ||
52-Week Range (€) | 0.655 - 2.56 | ||
Shares Outstanding (Mil) | 4.38 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 7 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Interpace Biosciences Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Interpace Biosciences Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Interpace Biosciences Inc Frequently Asked Questions
What is Interpace Biosciences Inc(STU:PF42)'s stock price today?
When is next earnings date of Interpace Biosciences Inc(STU:PF42)?
Does Interpace Biosciences Inc(STU:PF42) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |